Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans Remain

Johnson & Johnson (JNJ, Financial) has announced the termination of its phase 2 trial for the TAR-200 therapy aimed at treating patients with muscle-invasive bladder cancer (MIBC). The decision followed an interim analysis from the SunRISe-2 study, which indicated no advantage over existing chemo-radiation treatments.Despite this setback, the company remains committed to seeking FDA approval by early 2025 for TAR-200 as a monotherapy for non-muscle invasive bladder cancer (NMIBC). Johnson & Johnson expresse ...